Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells

Vaccine

Volumn 28, Issue 22, 2010, Pages 3848-3855

  Hussain, Althaf I ^a   Cordeiro, Melissa ^a   Sevilla, Elizabeth ^a   Liu, Jonathan ^a  

^a MedImmune   (United States)

Author keywords

Live attenuated influenza vaccine (LAIV); MDCK

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL CULTURE; CHICKEN; COMPARATIVE STUDY; CONTROLLED STUDY; EGG; HOST RANGE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; VACCINE PRODUCTION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CELL LINE, TUMOR; CHICKENS; DOGS; EGGS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; RNA, VIRAL; VACCINES, ATTENUATED; VIRUS REPLICATION;

EID: 77952319322     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.005     Document Type: Article

References (28)

1. Belshe R.B., and Gruber W.C. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent intranasal influenza vaccine in adults and children. Philos Trans R Soc Lond Ser B: Biol Sci 356 (2001) 1947-1951
2. Belshe R.B., Nichol K.L., Black S.B., Shinefield H., Cordova J., Walker R., et al. Safety, efficacy and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 39 (2004) 920-927
3. Belshe R.B., Lee M.-S., Walker R.E., Stoddard J., and Mendelman P.M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vac 3 6 (2004) 643-654
4. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 (2003) 1769-1775
5. Mathews J. Egg-based influenza vaccine production-30 years of commercial experience and our future expectations for cell culture. National academy of engineering and institute of medicine conference, vaccine production engineering approaches to a pandemic. Washington, DC, April 10-11 (2006)
6. Fedson D.S. New technologies for meeting the global demand for pandemic influenza vaccines. Biologicals 36 (2008) 346-349
7. Gerdil C. The annual production cycle of influenza vaccine. Vaccine (2003) 1776-1779
8. Audsley J.M., and Tannock G.A. Cell-based Influenza vaccines: progress to date. Drugs 68 11 (2008) 1483-1491
9. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccines in infants and young children. N Engl J Med 3 56 7 (2007) 685-696
10. King J.C., Stoddard J., Gaglani M.J., Moore K.A., Magder L., McClure E., et al. Effectiveness of school-based influenza vaccination. N Engl J Med 355 24 (2006) 2523-2532
11. Ambrose C.S., Luke C., and Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir Viruses 2 (2008) 183-192
12. Liu J., Shi X., Schwartz R., and Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 27 (2009) 6460-6463
13. Turpin E., Luke K., Jones J., Tumpey T., Konan K., and Schultz-Cherry S. Influenza virus infection increased p53 activity: role of p53 in cell death and viral replication. J Virol 79 14 (2005) 8802-8811
14. Veckman V., Osterlund P., Fagerlund R., Melen K., Matikainen S., and Julkunen I. TNF- and IFN-enhance influenza A virus induced chemokine gene expression in human A549 lung epithelial cells. Virology 345 (2006) 96-104
15. Hierholzer J.C., Castells E., Banks G.G., Bryan J.A., and McEwen C.T. Sensitivity of NCI-H292 human lung mucoepidermoid cells for respiratory and other human viruses. J Clin Microbiol 31 6 (1993) 1504-1510
16. Brydon E.W.A., Smith H., and Sweet C. Influenza A virus induced apoptosis in bronchiolar epithelial (NCI-H292) cells limits pro-inflammatory cytokine release. J Gen Virol 84 (2003) 2389-2400
17. Recommended composition of influenza virus vaccines for use in 2006-2007 influenza season. WHO, Weekly Epidemiol Rec 9 81 (2006) 81-88
18. ®/CAIV-T vaccine throughout the manufacturing process. Vaccine 24 (2006) 2151-2160
19. Govorkova E.A., Murti G., Meigner B., De Taisne C., and Webster R.G. African green monkey (Vero) cells provide and alternate host cell system for influenza A and B viruses. J Virol 70 8 (1996) 5519-5524
20. Liu J., Mani S., Schwartz R., Richman L., and Tabor D.E. Cloning and assessment of tumorigenecity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 28 (2010) 1285-1293
21. Oh D.Y., Barr I.G., Mosse J.A., and Laurie K.L. MDCK-SIAT1 cell show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol 46 7 (2008) 2189-2194
22. Tannock G.A., and Audsley J.M. The growth of attenuated influenza vaccine donor strains in continuous cell lines. J Virol Methods 123 (2005) 187-193
23. Romanova J., Katinger D., Ferko B., Voglauer R., Mochalova L., Bovin N., et al. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology 307 (2003) 90-97
24. Halperin S.A., Smith B., Mabrouk T., Germain M., Trepanier P., Hassell T., et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in health adults, seniors and children. Vaccine 20 78 (2002) 1240-1247
25. Pau M.G., Ophorst C., Koldijk M.H., Schouten G., Mehtali M., and Uydehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19 17-19 (2001) 2716-2721
26. Koudstaal W., Hartgroves L., Havenga M., Legastelois I., Ophorst C., Sieuwerts M., et al. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 27 (2009) 2588-2593
27. McPherson C.E. Development of a novel recombinant influenza vaccine in insect cells. Biologicals (2008) 350-353
28. Shoji Y., Chichester J.A., Bi H., Musichuk K., de la Rosa P., Goldschmidt L., et al. Plant expressed HA as a season influenza vaccine candidate. Vaccine 26 (2008) 2930-2934